- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06468709
A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence
June 16, 2024 updated by: ZOU DUOWU, Ruijin Hospital
A Prospective, Randomized Controlled Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence Patients Receiving Glucocorticoid Maintenance Therapy/Glucocorticoid Combined With MMF Maintenance Therapy
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas.
In China, type I AIP is predominant.
Glucocorticoids (GC) have a significant therapeutic effect.
Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy.
Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients.
Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc.
Among them, the incidence of adverse reactions in MMF is relatively low.
As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients.
The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas.
It can be divided into type I AIP and type II AIP.
In China, type I AIP is predominant, accompanied by elevated IgG4 levels, diffuse or segmental pancreatic enlargement, and irregular narrowing of the pancreatic duct.
Glucocorticoids (GC) have a significant therapeutic effect.
Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy.
Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients.
The International Pancreatic Society has released an international consensus on AIP, indicating that the risk factors for AIP recurrence are still unclear.
The following are possible signs of recurrence: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs.Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc.
Among them, the incidence of adverse reactions in MMF is relatively low.
As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients.
The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.Main research objective: To evaluate the impact of corticosteroid monotherapy and corticosteroid combined with MMF maintenance therapy on disease remission rate in high-risk type I AIP patients with recurrence within 3 years Secondary research objective: (I) To evaluate the impact on endocrine function; (II) Evaluate the impact on external secretion function; (III) Evaluate the impact on the incidence of malignant tumors; (IV) Adverse reactions; (V) Treatment costs
Study Type
Interventional
Enrollment (Estimated)
86
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: XIaonan Shen, Doctor
- Phone Number: 18817554263
- Email: hgssldsxn@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital
-
Contact:
- Shen, Doctor
- Phone Number: 18817554263
- Email: hgssldsxn@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent form with date;
- Promise to comply with research procedures and cooperate with the implementation of the entire process research;
- Age 18 and above, regardless of gender;
- Confirmed as type I AIP and high-risk for recurrence, including the following characteristics: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs;
- Indications for treatment, (1) symptomatic individuals may experience pancreatic involvement (such as obstructive jaundice, abdominal pain, lower back pain, etc.) and extrapancreatic organ involvement (such as jaundice caused by bile duct stenosis, etc.); (2) Asymptomatic individuals, who may develop subclinical AIP (persistent pancreatic mass, liver dysfunction with proximal IgG4 associated sclerosing cholangitis) with severe and irreversible damage to important organs;
- Able to persist and cooperate with research interventions, such as oral medication;
- If it is a woman in the reproductive period, contraception should be used for at least one month before screening, and a commitment should be made to use contraception throughout the entire study period and continue until the specified time after the end of the study
Exclusion Criteria:
- Pregnant/lactating women; Inability or refusal to sign informed consent form;
- History of mental illness;
- Allergy to research interventions;
- With malignant tumors;
- Active hepatitis/tuberculosis and other infectious diseases;
- With underlying diseases that are difficult to control, such as severe heart failure, respiratory failure, etc;
- Within 3 months, use of glucocorticoids or immunosuppressants due to other illnesses
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Glucocorticoids group
Induction therapy: Prednisone 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d
|
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio.
The randomization sequence was generated online using a computer randomization scheme.
Group A was the GC monotherapy maintenance group
Other Names:
|
Experimental: Glucocorticoids+MMF group
GC: Induction therapy: 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d.
At the initial stage of simultaneous treatment, 1.0g-1.5g
MMF combined with GC treatment
|
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio.
The randomization sequence was generated online using a computer randomization scheme.
Group B was the GC+MMF maintenance group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the impact of monotherapy with glucocorticoids and glucocorticoid combined with MMF maintenance therapy on disease remission rate in high-risk type I AIP patients for recurrence within 3 years
Time Frame: 3 years
|
to evaluate the disease remission rate of monotherapy with glucocorticoids and glucocorticoid combined with MMF maintenance therapy in high-risk type I AIP patients within 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the impact on endocrine function
Time Frame: 3 years
|
to evaluate the incidence rate of diabetes mellitus, including measuring Hb1Ac, C peptide, insulin secretion.
|
3 years
|
Evaluate the impact of external secretion pancreatic function
Time Frame: 3 years
|
to evaluate the incidence rate of external secretion disfunction of pancreas including the level of vitamin, 25-OH-D3
|
3 years
|
Assess the impact on the incidence of malignant tumors
Time Frame: 3 years
|
to assess the impact on the incidence of gastrointestinal tumors by endoscopies
|
3 years
|
Adverse reactions
Time Frame: 3 years
|
Adverse reactions including the allergic reactions to drugs
|
3 years
|
Treatment costs
Time Frame: 3 years
|
to assess the total treatment costs in 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Duowu Zou, Doctor, Ruijin Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 20, 2024
Primary Completion (Estimated)
March 31, 2027
Study Completion (Estimated)
July 31, 2027
Study Registration Dates
First Submitted
May 23, 2024
First Submitted That Met QC Criteria
June 16, 2024
First Posted (Estimated)
June 21, 2024
Study Record Updates
Last Update Posted (Estimated)
June 21, 2024
Last Update Submitted That Met QC Criteria
June 16, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Disease Attributes
- Pancreatic Diseases
- Pancreatitis
- Chronic Disease
- Pancreatitis, Chronic
- Recurrence
- Autoimmune Pancreatitis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
- Glucocorticoids
Other Study ID Numbers
- KY2024-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to share IPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 AIP
-
Second Affiliated Hospital of Guangzhou Medical...Unknown
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGCompletedType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Hadassah Medical OrganizationWithdrawnType 1 or 2 Diabetics
-
Hadassah Medical OrganizationUnknownUncontrolled Type 1 Diabetic Patients
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
Clinical Trials on Glucocorticoids
-
University Hospital Inselspital, BerneRoche Pharma AG; University of BernCompleted
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedMicroscopic Polyangiitis (MPA) | Granulomatosis With Polyangiitis (Wegener's) (GPA)United States, Belgium, France, United Kingdom, Denmark, Canada, Japan, Australia, New Zealand, Sweden, Czechia, Italy, Greece, Mexico, Norway
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Dong YangJilin UniversityEnrolling by invitationAcute Exacerbation of Chronic Obstructive Pulmonary DiseaseChina
-
Shenzhen Kangzhe Pharmaceutical Co., Ltd.LanZhou University; Beijing Friendship Hospital; The Third Affiliated Hospital... and other collaboratorsRecruiting
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingVasculitis | Granulomatosis With Polyangiitis | Wegener GranulomatosisUnited States
-
Wake Forest University Health SciencesCompletedHyperglycemia | Type 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
ChemoCentryxCompletedANCA-associated VasculitisUnited States, Canada
-
Rheumazentrum RuhrgebietCompletedRheumatoid ArthritisGermany
-
Institute of Hematology & Blood Diseases HospitalUnknownUrination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,China